A Bicentric Open-label, Randomized, Two-parallel-group Study Investigating the Impact of Combined Lantus Insulin Glargine) and Lyxumia(Lixisenatide) on Insulin Secretion and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled on Diet and Oral Antidiabetic Medication
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2015
Price : $35 *
At a glance
- Drugs Insulin glargine (Primary) ; Lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 21 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.